ethyl 4-<3-<(methoxy)methoxy>phenyl>-3-oxobutanoate | 160721-42-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 4-<3-<(methoxy)methoxy>phenyl>-3-oxobutanoate
• 英文别名: ethyl 4-[3-(methoxymethoxy)phenyl]-3-oxobutanoate
• CAS: 160721-42-6
• 化学式: C₁₄H₁₈O₅
• 分子量: 266.294
• InChiKey: LQLZLFZPKGPPTM-UHFFFAOYSA-N

物化性质

• 沸点：
  369.5±32.0 °C(Predicted)
• 密度：
  1.129±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 4-<3-<(methoxy)methoxy>phenyl>-3-oxobutanoate 在 ethandithiol 、 BF₅O 、 camphor-10-sulfonic acid 、 二异丁基氢化铝 、 对甲苯磺酸 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 29.33h， 生成 3,3-ethylenedioxy-1,8-dihydroxy-1,2,3,4-tetrahydronaphthalene
  参考文献：
  名称：

  Regioselective synthesis of 1,8-dihydroxytetralins through a tandem reduction/intramolecular hydroxyalkylation of 4-(3-hydroxyphenyl)alkanoates

  摘要：

  A series of 4-(3-hydroxyphenyl)butanoates 3 has been prepared and transformed into 1,8-dihydroxytetralins of general formula 2 by treatment with 2 equivalents of DIBALH followed by quenching with aqueous NH4Cl. A possible mechanism for this novel totally regioselective intramolecular hydroxyalkylation is suggested and the factors affecting the stability of 1,8-dihydroxytetralins 2 are also discussed.

  DOI：

  10.1016/s0040-4020(01)89307-8
• 作为产物：
  描述：

  ethyl potassium malonate 在 N,N'-羰基二咪唑 、 magnesium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 ethyl 4-<3-<(methoxy)methoxy>phenyl>-3-oxobutanoate
  参考文献：
  名称：

  EP1535915

  摘要：

  公开号：

文献信息

• FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1535915A1

  公开（公告）日：2005-06-01

  The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R1 is a hydrogen atom or an optionally substituted hydrocarbon group, R2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X1 is an oxygen atom or a sulfur atom, X2 is a bond, an oxygen atom or -S(O)n- (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, -S(O)m-, -C(=O)-N(R3)- or -N(R3)-C(=O)- (R3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M1, M2 and M3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.

  本发明提供了一种由式（I）表示的化合物： [其中 R 为任选取代的烃基或任选取代的杂环基，p 为 0、1 或 2，当 p 为 2 时，每个 R 可以相同或不同，R1 为氢原子或任选取代的烃基，R2 为任选取代的芳香基、环 A 是任选取代的单环芳香环或任选取代的双环芳香融合环，X1 是氧原子或硫原子，X2 是键、氧原子或 -S(O)n- （其中 n 是 0、1 或 2），Y 是键、氧原子、-S(O)m-、-R3是氢原子、任选取代的烃基或任选取代的杂环基，m是0、1或2），M1、M2和M3可以相同或不同，各自独立地是键或任选取代的二价脂族烃基、和 M4 是任选取代的二价脂族烃基]或其盐，可用作脂质代谢异常、动脉硬化疾病及其后遗症、糖尿病等的预防和/或治疗剂。
• Furan or thiopene derivative and medicinal use thereof
  申请人：Hamamura Kazumasa

  公开号：US20060100261A1

  公开（公告）日：2006-05-11

  The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R 1 is a hydrogen atom or an optionally substituted hydrocarbon group, R 2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X 1 is an oxygen atom or a sulfur atom, X 2 is a bond, an oxygen atom or —S(O) n — (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, —S(O) m —, —C(═O)—N(R 3 )— or —N(R 3 )—C(═O)— (R 3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M 1 , M 2 and M 3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M 4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.

  本发明提供了一种由式（I）表示的化合物： [其中 R 为任选取代的烃基或任选取代的杂环基，p 为 0、1 或 2，当 p 为 2 时，每个 R 可以相同或不同，R 1 是氢原子或任选取代的烃基，R 2 是任选取代的芳香基团，环 A 是任选取代的单环芳香环或任选取代的双环芳香融合环，X 1 是氧原子或硫原子，X 2 是键、氧原子或 -S(O) n - 其中 n 为 0、1 或 2），Y 为键、氧原子、-S(O) m -、-C(═O)-N(R 3 )-或-N(R 3 )-C(═O)-(R 3 是氢原子、任选取代的烃基或任选取代的杂环基，且 m 是 0、1 或 2），M 1 , M 2 和 M 3 可以相同或不同，且各自独立地为键或任选取代的二价脂族烃基，以及 M 4 是任选取代的二价脂族烃基]或其盐，可用作脂质代谢异常、动脉硬化疾病及其后遗症、糖尿病等的预防和/或治疗剂。
• US7553867B2
  申请人：——

  公开号：US7553867B2

  公开（公告）日：2009-06-30
• EP1535915
  申请人：——

  公开号：——

  公开（公告）日：——
• Regioselective synthesis of 1,8-dihydroxytetralins through a tandem reduction/intramolecular hydroxyalkylation of 4-(3-hydroxyphenyl)alkanoates
  作者：Giuseppe Guanti、Luca Banfi、Renata Riva

  DOI：10.1016/s0040-4020(01)89307-8

  日期：1994.1

  A series of 4-(3-hydroxyphenyl)butanoates 3 has been prepared and transformed into 1,8-dihydroxytetralins of general formula 2 by treatment with 2 equivalents of DIBALH followed by quenching with aqueous NH4Cl. A possible mechanism for this novel totally regioselective intramolecular hydroxyalkylation is suggested and the factors affecting the stability of 1,8-dihydroxytetralins 2 are also discussed.